Cellular based treatment modalities for unresectable hepatocellular carcinoma.

Core Tip: Over the recent years investigation for safe and effective treatments for unresectable hepatocellular carcinoma (HCC) has shifted focus from various chemotherapeutic agents to immune based therapy. Although far from being finalized, immune cell-based therapy has shown efficacy in a variety of clinical trials, indicating possible future utilization alone or in combination for the prevention and treatment of HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC) is a malignant primary tumor of the liver, accounting for approximately ninety percent of total liver tumor cases worldwide[ 1 ]. HCC commonly occurs in patients with preexisting liver cirrhosis, chronic hepatitis B virus (HBV), chronic hepatitis C virus (HCV), heavy alcohol consumption, aflatoxin exposure and metabolic associated fatty liver disease associated with diabetes and metabolic syndrome[ 2 ]. According to the Global Cancer Observatory (GLOBOCAN) in 2020, HCC is considered the 6 th most common cancer worldwide, with the highest incidence in eastern Asia and Africa[ 3 ]. It has been estimated that by 2025, there will be more than one million individuals diagnosed with liver cancer annually[ 4 ]. Worldwide incidence of HCC has shown a greater predominance among men in comparison to women, with most diagnoses made in patients over the age of 60 years old[ 5 ]. HCC risk factors in the United States have varied significantly over the last two decades, with a majority of cases currently related to chronic HCV infection[ 6 ].

Management of HCC varies depending on the staging status of the tumor according to the standardized Barcelona-Clinic Liver Cancer (BCLC) system endorsed by both the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases[ 7 ]. Locally diagnosed tumors (BCLC stages 0-A), which are small in size (≤ 3 cm), early in progression, and limited to the liver parenchyma are amendable to surgical resection, radiofrequency ablation or ideally liver transplantation[ 8 ], with a median survival rate of 60 mo[ 9 ]. Advanced HCC on the other hand is defined by a significant increase in tumor size, vascular invasion and/or metastatic disease that is not amenable to loco-regional therapy (BCLC Stage C-D)[ 10 ], warranting treatment with systemic therapy[ 11 ]. In cases necessitating liver transplantation, the Milan criteria has been adopted by The United Network for Organ Sharing in order to determine eligibility[ 12 ], however this approach is limited by organ availability[ 13 ].

For over a decade, sorafenib has been considered the first line systemic treatment for advanced HCC. More recently, other systemic treatments such as the tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), immune checkpoint inhibitors (ICIs) (atezolizumab, ipilimumab, nivolumab, pembrolizumab) and the monoclonal antibody ramucirumab have been approved as first- and second-line treatment options[ 14 ]. With only modest established improvement in overall survival (OS) and an assortment of adverse effects, there has been a recent push for the development of immunobiological treatments, which first demonstrated efficacy in the treatment of hematological cancers. Treatments include chimeric antigen receptor-T cells (CAR-T cells), T cell receptor (TCR) engineered T cells, dendritic cells (DC), natural killer (NK) cells, and tumor infiltrating lymphocyte (TIL) cellular therapies (Figure 1 ). In this article we will review the novel range of cellular based treatments for HCC non-amenable to loco-regional therapy and introduce readers to various preclinical and clinical trials investigating their efficacy.

SYSTEMIC THERAPIES: APPROVED FIRST LINE THERAPIES

Sorafenib

Sorafenib is a multi-kinase inhibitor that inhibits cellular proliferation and angiogenesis through its effects on various receptor tyrosine kinases including vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and c-kit[ 15 ]. Its efficacy was demonstrated in two large phase III randomized controlled trials; SHARP conducted in the United States and Europe, and a similar study conducted in the Asia- Pacific focusing on patients with unresectable and advanced HCC[ 16 ]. In the SHARP trial, median OS was increased to 10.7 mo compared to 7.9 mo in placebo[ 17 ]. Similar findings were demonstrated in the Asia-Pacific trial; median OS increased in the treatment group (6.5 mo vs 4.2 mo) and time-to-progression (TTP) was also significantly greater (2.8 mo vs 1.4 mo)[ 18 ]. These findings led to sorafenib being approved by the Food and Drug Administration (FDA) in 2007, making it the standard of care and first line treatment option of advanced HCC[ 15 , 19 ].

Lenvatinib

Lenvatinib is another inhibitor of multiple receptor tyrosine kinases that has recently gained much attention[ 20 ]. In the randomized, open-label, non-inferiority phase III trial (REFLECT), lenvatinib was compared to sorafenib in patients who were deemed to have non-resectable HCC. Findings indicated an improved median OS of 13.6 mo with lenvatinib, compared to 12.3 mo with sorafenib. Lenvatinib also demonstrated an increase in median progression-free survival (PFS) and overall response rate (ORR)[ 21 ]. This allowed for FDA approval in 2018 as a fist line agent for treatment of unresectable HCC[ 22 ].

SYSTEMIC THERAPIES: APPROVED SECOND LINE THERAPIES

Ramucirumab

The phase III randomized controlled trial REACH ( NCT01140347 ) investigated ramucirumab, a monoclonal antibody against VEGF receptor 2. While the study failed to demonstrate prolonged OS in the entire cohort, patients with elevated serum alpha-fetoprotein (AFP) (> 400 ng/mL) had significantly longer median OS when compared to placebo (7.8 mo vs 4.2 mo, P = 0.006)[ 23 ]. A subsequent phase III study, REACH-2 ( NCT02435433 ) reported a significantly prolonged median OS (8.5 mo vs 7.3 mo) in sorafenib-experienced patients receiving ramucirumab vs placebo with AFP of 400 ng/mL or greater[ 24 ]. These findings showed promise as an effective treatment option in those with elevated AFP, leading to FDA approval in May 2019.

Regorafenib

Regorafenib is a multikinase inhibitor that inhibits various molecules including VEGF receptor 2/3, PDGF receptor and fibroblast growth factor receptor 1[ 25 ]. In the randomized, double-blind, phase III clinical trial RESORCE ( NCT01774344 ) patients who failed sorafenib therapy were assigned to receive regorafenib vs placebo. This study determined that regorafenib significantly improved OS in individuals who experienced radiological progression of HCC during sorafenib treatment (10.6 mo vs 7.8 mo, P < 0.0001)[ 26 ]. Based on the promising findings of the RESORCE trial and a tolerable safety profile, the FDA approved regorafenib as a second line treatment option in those who have HCC progression while on sorafenib or who are not eligible for alternative therapy[ 25 ].

Cabozantinib

A double-blind, phase III clinical trial CELESTIAL ( NCT01908426 ) was conducted testing cabozantinib, a multikinase inhibitor, in patients with unresectable HCC who had progressed with sorafenib. The study demonstrated a significant prolongation of OS when compared to placebo (10.2 mo vs 8.0 mo, P = 0.005) coupled with a longer median PFS when compared to placebo[ 27 ] . Based on the findings of CELESTIAL, the FDA approved cabozantinib as a second line treatment option for HCC in those who have undergone previous therapy with sorafenib .

IMMUNOTHERAPY: ICIS

Limited efficacy and undesirable side effects of traditional therapies ( i.e. , sorafenib) have led to further investigation of immunotherapeutic agents over the years. A recent and emerging field of treatment includes cancer immunotherapies using ICIs that target programmed cell death protein-1 and its ligand (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein- 4 (CTLA-4), which has significantly altered treatment of various types of cancer including HCC[ 28 ].

Immune checkpoint molecules play essential roles in regulating cancer cell interactions with the host immune system; and the development of drugs that suppress these interactions used by tumor cells to evade host immunity has shown promising results. PD-1, a member of CD28, is expressed on activated immune cells including T cells, B cells, and myeloid cells; and its interaction with ligand PD-L1 negatively regulates the immune system through suppressive signals that induce peripheral tolerance[ 29 ]. In HCC tumor cells, PD-L1 is aberrantly expressed, allowing for such an escape from host immunity[ 30 ]. CTLA-4 is another member of the CD28 family, and it is induced on T cells by antigen activation leading to subsequent binding with CD80 and CD86 with more affinity compared to CD28, negatively regulating costimulatory T cell signals and allowing for peripheral tolerance[ 31 ]. Ultimately these immunotherapeutic drugs strategically suppress key checkpoints that may be used by tumor cells to evade the host immune system, hindering a hallmark for tumor progression.

Atezolizumab

Atezolizumab is a fully humanized monoclonal antibody targeting PD-L1 that has recently changed the treatment landscape of unresectable HCC. A phase-Ib study evaluating synergistic atezolizumab and bevacizumab (anti-VEGF antibody) in patients with previously untreated and unresectable HCC not only demonstrated an acceptable safety profile, but promising antitumor activity with ORR 36%, disease control rate (DCR) 71%, and a median PFS of 7.3 mo when compared to monotherapy with nivolumab or pembrolizumab[ 32 ]. These results led to IMbrave150 ( NCT 03434379 ), an open-label, randomized phase III study assessing atezolizumab (anti-PDL1) in combination with bevacizumab (anti-VEGF antibody) compared to sorafenib in patients with untreated locally advanced or metastatic HCC. OS at 12 mo was significantly longer in the combination group when compared to sorafenib (67.2% vs 54.6%) and PFS was significantly longer in atezolizumab + bevacizumab vs sorafenib (6.8 mo vs 4.3 mo, hazard ratio for disease progression or death [0.59; 95% confidence interval (CI): 0.47-0.76, P < 0.001], leading to FDA approval in May 2020 for the treatment of unresectable or metastatic HCC who have not received prior systemic therapy[ 33 ]. Currently a phase III, multicenter study of atezolizumab plus bevacizumab vs active surveillance as adjuvant therapy in HCC at high risk of recurrence after surgical resection or ablation is recruiting (IMbrave050; NCT04102098 )[ 34 ]. In addition, a phase III study evaluating the safety and efficacy of atezolizumab plus levantinib or sorafenib vs levantinib or sorafenib alone in locally advanced or metastatic and/or unresectable HCC following prior treatment with combination atezolizumab and bevacizumab was recently posted in February 2021 (IMbrave251; NCT04770896 ).

Ipilimumab

Ipilimumab is a monoclonal antibody targeting CTLA-4, which was recently granted accelerated FDA approval in May 2020, when used in combination with nivolumab (anti-PD-1) for HCC that has previously been treated with sorafenib. Approval was based on a single arm of the phase I/II clinical trial CheckMate 040 ( NCT01658878 ), in which patients were treated with nivolumab 3 mg/kg plus ipilimumab 3 mg/kg every 3 wk for 4 doses. In addition to a substantial reduction in tumor burden, the overall ORR was 32%, with median OS 22.8 mo while having manageable safety profiles[ 35 ]. A phase III trial of ipilimumab in combination with nivolumab vs sorafenib or levantinib as first line treatment in patients with advanced HCC is currently recruiting participants (CheckMate 9DW; NCT04039607 ). A variety of clinical trials evaluating ipilimumab in combination with nivolumab during various treatment phases are ongoing and include; prior to liver resection (PRIME-HCC; NCT03682276 ), as neoadjuvant therapy ( NCT03510871 ), and in combination with trans-arterial chemoembolization (CheckMate 74W; NCT04340193 ).

Nivolumab

Nivolumab is an anti-PD-1 monoclonal antibody that has shown promising results, leading to FDA approval for second-line treatment of advanced HCC. The phase I/II clinical trial CheckMate 040 ( NCT01658878 ) investigated nivolumab in sorafenib-naïve and sorafenib-experienced patients with intermediate-advanced HCC and Child-Pugh Stage A. During the dose-expansion phase, ORR was 20%, while DCR was 64% with a median progression free survival of 4.1 mo[ 36 ]. The subsequent phase III study CheckMate 459 (NCT2576509) evaluating nivolumab vs sorafenib as first line treatments for unresectable HCC failed to demonstrate statistical significance for the primary endpoint of OS[ 37 ]. Currently a phase III trial, CheckMate-9DX ( NCT 03383458 ), is actively evaluating recurrence free survival (RFS) in those with HCC at high risk of recurrence after curative hepatic resection or ablation.

Pembrolizumab

Pembrolizumab is a humanized anti-PD-1 monoclonal antibody that has been investigated across a variety of malignancies[ 38 ]. The phase II open-label clinical trial KEYNOTE-224 ( NCT02702414 ) studied the safety and efficacy of pembrolizumab in patient with advanced HCC after having failed treatment with sorafenib. Favorable findings included an ORR of 17%, DCR of 61%, along with PFS of 4.8 mo, median OS of 12.9 mo and TTP of 4.9 mo[ 39 ]. This promising data led to FDA approval in November 2018 as a second line treatment after sorafenib. A subsequent phase III double-blind, randomized control trial, KEYNOTE-240 ( NCT02702401 ) compared pembrolizumab to placebo, demonstrated longer OS and PFS; however, these findings were not statistically significant and failed to meet primary endpoints[ 40 ]. There are currently two-phase III trials that are ongoing at the time of this publication; KEYNOTE-394 ( NCT03062358 ) , evaluating pembrolizumab in Asian patients with systemically treated advanced HCC and KEYNOTE-937 ( NCT03867084 ) as an adjuvant therapy in HCC after curative treatment[ 29 ].

Ultimately, cancer uses a variety of unique mechanisms to evade host immune response and to develop drug resistance in HCC. This has sparked much interest in combining treatment modalities, particularly combination ICIs and checkpoint inhibitors with other chemotherapeutics. HIMALAYA ( NCT03298451 ) is an open-label, multi-center, phase III study assessing durvalumab (anti-PDL1) plus tremelimumab (anti-CTLA4) in patients with advanced HCC. Scientists and physicians alike are eagerly awaiting results of other ongoing phase III trials such as LEAP-002 ( NCT03713593 ) evaluating pembrolizumab and levantinib in combination and COSMIC-312 ( NCT03755791 ) investigating atezolizumab and cabozantinib synergistically.

BEYOND CHECKPOINT INHIBITORS

Cell based immunotherapy

In recent years cancer therapy has begun shifting focus from the aforementioned conventional therapies, to the use of immune cell therapies, which utilize the host immune system to target and treat cancer. One such avenue of therapy includes gene modified T cell therapy, particularly TCR engineered T cells and CAR-T cells, which have shown promise in various malignancies and continue to be tested in clinical trials targeting HCC. Below we will discuss the concept of gene modified T cell therapies, and other modalities of adoptive cell transfer while reporting the results of recent and ongoing clinical trials where applicable.

When engineering T-cell based immune cell therapies targeting HCC, identification of tumor-associated antigens (TAAs) that can allow for appropriately mediated immune response is critical. AFP is a glycoprotein composed of 591 amino acids, identified as the first oncofetal biomarker for patients with HCC allowing for quantitative estimation of tumor burden and response to therapy[ 41 ]. Elevated levels of AFP have been found in approximately 70% of patients diagnosed with HCC, however elevations can also be found in other pathological conditions including cirrhosis, various hepatic disorders, germ cell tumors, lung cancer, gastric cancer, and pancreatic cancer[ 42 ]. Pre-clinical models have demonstrated the potential of AFP in the development of cellular immunotherapies[ 43 , 44 ]. Glypican-3 (GPC-3) belongs to the transmembrane heparan sulfate proteoglycan family, that regulates cellular division and growth[ 45 ]. GPC-3 expression is elevated in HCC, and recent studies have demonstrated that elevated levels correlate with an overall worse prognosis[ 46 ]. Therefore GPC-3 has been investigated in pre-clinical studies as a target for adoptive cell immunotherapy[ 47 , 48 ]. Melanoma antigen gene proteins (MAGE) was first identified in melanoma patients and has been found to be almost exclusively expressed in a variety of cancer tissues. Aberrant expression of MAGE has been demonstrated to significantly correlate with clinical characteristics of HCC, however functions of the multitude of MAGE proteins have yet to be thoroughly understood[ 49 ]. New York esophageal squamous cell carcinoma (NY-ESO-1) is a member of the cancer testis antigen family expressed in a variety of cancer cells including HCC[ 50 ]. NY-ESO-1 has been deemed as the most promising cancer testis antigen for the development of cancer immunotherapy with a multitude of studies demonstrating promising results across a variety of malignancies[ 51 ]. When examining HCC caused by viral infection (HBV or HCV) there is prospect in targeting viral antigens as a strategy to etiologically treat HCC. Targets include HBV S or L protein (envelope proteins), which have shown promise by eliminating HBV positive hepatocytes when targeted by antigen specific T cells[ 52 ]. Targeting of hepatitis B surface antigen has also shown efficacy in mouse models utilizing CAR-T cell therapy as well[ 53 ]. Other tumor antigens that are of particular interest include epithelial cell adhesion molecules (EpCAM)[ 54 ], mucin 1 glycoprotein (MUC1)[ 55 ] and human telomerase reverse transcriptase (hTERT)[ 56 ].

CAR-T and TCR engineered T cells: The basics

Gene modified T cell therapy is a method used to deliver T cells that are genetically engineered to produce TCRs that recognize specific tumor associated antigens and their epitopes. There are currently two methods of developing gene modified T cells, CAR-T cells and TCR transgenic T-cells (engineered T-cells), which have both shown efficacy and promise in a variety of solid and hematological malignancies[ 57 ]. CAR is composed of three basic elements: (1) the extracellular antigen recognition domain, (2) the transmembrane domain and (3) the intracellular signaling domain. The extracellular portion is a single chain antigen recognition receptor composed of heavy and light chains of a monoclonal antibody specific to the tumor surface antigen, allowing for no restrictions of target antigen recognition by major histocompatibility complex (MHC) molecules. The intracellular portion is formed by combining co-stimulatory molecules to the intracellular portion of TCRs[ 58 ]. The basic process of CAR-T generation includes: (1) T cell isolation from peripheral blood mononuclear cells using immunoselective beads and activation with anti-CD3 and Il-2, (2) genetic modification of CAR-T, (3) expansion of T cells in vitro , (4) evaluation ensuring CAR expression and T cell viability, and (5) CAR-T infusion back into the patient[ 59 ]. TCR transgenic T cells possess a TCR on the surface consisting of two distinct protein chains; alpha and beta, which bind to the MHC of antigen presenting cells, allowing for a highly specific interaction which is not limited to membrane bound antigens[ 60 , 61 ]. As previously described the selection and validation of target antigens is of utmost importance when designing both TCR-T cells and CAR-T cells that are efficacious and minimize on target/off-tumor side effects[ 62 ].

CAR-T immunotherapy

CAR-T cell therapy has been tested both preclinically and clinically when targeting HCC. Below we will discuss findings of completed and ongoing clinical studies that seek to demonstrate safety and efficacy of cellular therapy. Shi et al [ 63 ] recently published results from two prospective phase I trials involving GPC-CAR-T cells ( NCT02395250 and NCT03146234 ) in patients with advanced GPC3 positive relapsed or refractory HCC following chemotherapeutic induced lymphodepletion. A total of 13 patients received CAR-T cell infusion, with two partial responses and one patient with sustained stable disease after 44.2 mo. OS rates at 3 years, 1 year, and 6 mo were 10.5%, 42% and 50.3% respectively with median OS duration of 278 d according to the Kaplan-Meier method. Unfortunately, toxic effects were noted with major concern as one patient developed cytokine release syndrome (CRS) leading to death from multi-organ failure[ 63 ]. A recently completed, open-label, phase I-II study by Dai et al [ 64 ] demonstrated efficacy of CD133-CAR-T cell therapy in patients with biopsy proven HCC (BCLC stage C) not amenable to curative treatment. One patient demonstrated a partial response, while 66.7% of patients had stable disease after infusion with an overall PFS of 6.8 mo and median OS of 12 mo ( NCT02541370 ). Currently an open-label, single center, phase I-II study is underway investigating CAR-T/TCR-T cell immunotherapy targeting a variety of different malignancies including hepatoma ( NCT03638206 ). A list of currently ongoing clinical trials investigating CAR-T cells for the treatment of HCC is listed in (Table 1 ).

Improving CAR-T delivery and efficacy

Proven clinical efficacy of CAR-T across a variety of hematological malignancies has led to the investigation of its use in solid tumors. However, treatment of solid tumors poses many challenges to clinical investigators, one of which includes access to the tumor site. Many cases of HCC occur on the background of a fibrosed and cirrhotic liver, and the presence of such fibrotic extracellular matrix (ECM) poses a barrier for CAR-T cell penetration. In order to overcome such a challenge, CAR-T cells co-expressing heparinase, which degrades ECM heparan sulfate proteoglycans were developed. These newly engineered CAR-T cells improved cellular ability to degrade the ECM and displayed antitumor activity, suggesting a feasible strategy for the development of CAR-T cells targeting stroma-rich solid tumors[ 65 ]. Similar strategies are being investigated with the use of matrix metalloproteinase 8, which can allow CAR-T cells to overcome physical barriers[ 66 ]. Local administration of immunotherapy directly into tumors has shown promising results for organ selective delivery. In a study conducted by Katz et al [ 67 ], not only were CAR-T cells detected in biopsies of liver metastasis, but effective CAR-T cellular response was noted within the tumor following delivery via hepatic artery infusion. Such results have paved light into the investigation of direct tumor inoculation via a variety of local administration techniques including hepatic artery infusion in a multitude of clinical trials. Novel delivery platforms including nanoparticles, scaffolds and other biomaterials are also being investigated as a safe and effective way to deliver immunotherapy to tumor cells while avoiding off-target adverse effects[ 68 ]. Recent findings from the 2020 study conducted by Ma et al [ 69 ], demonstrated superior targeting and anti-tumor capabilities of CAR-T cell membrane coated nanoparticles both in vivo and in vitro .

In addition to tumor location being inaccessible, the tumor microenvironment has been found to be detrimental to CAR-T cells in regard to their survival and proliferation. The consumption of glucose by malignant cells renders the surrounding environment hypoxic, acidic, and low in nutrients leading to oxidative stress; leaving glycolytic T cells unable to adequately function, ultimately hindering the immune response[ 70 , 71 ]. In order to help eliminate reactive oxygen species (ROS) accumulation, CAR-T cells co expressing catalase were designed, and were subsequently able to survive and function in such unfavorable environments[ 72 ]. However, oxidative stress with release of compounds such as ROS and hydrogen peroxide, not only prevents recruitment and adequate function/persistence of immune cells, it also allows for recruitment of immune suppressor cells that lead to CAR-T cell exhaustion[ 73 ]. Strategies to help overcome such exhaustion include the use of ICIs that target PD-1, PD-L1, CTLA-4 in conjunction to CAR-T cells administration[ 74 ], and by genetically deleting T-cell PD-1 protein with the use of CRISPR-CAS9 gene editing[ 75 ]. There is optimism that these findings coupled with continued advancements in biomedical engineering will allow for new delivery and tumor microenvironment altering capabilities that can help amplify immunotherapeutic response in the treatment of HCC.

Improving CAR-T safety

When utilizing cellular immunotherapy with CAR-T cells, a number of important safety concerns are to be noted including CRS, central nervous system toxicity (CNS) and the “on target-off tumor” effect. CRS is characterized by flu like symptoms including fever, fatigue and headache, which can progress to hypotension and organ dysfunction secondary to uncontrolled systemic inflammatory response associated with elevated serum cytokines; particularly interleukin (IL)-6, IL-10, tumor necrosis factor α (TNF-α) and interferon (IFN)-γ[ 76 ]. Symptoms of CNS toxicity can range from headache and dizziness, to memory loss and delirium, and can be found along with CRS or after the resolution of CRS. Although the exact etiology remains unclear at this time, it is speculated that various cytokines may alter the blood brain barrier[ 77 ], in conjunction with an increase in protein, white blood cells, IFN-γ, TNF-α, and IL-6 within cerebrospinal fluid[ 78 ].

These adverse reactions stem from CAR-T cells recognizing TAAs, which are not only heterogenous amongst tumors, but can also be present in normal tissues, elevating the risk of off target toxicity[ 71 ]. Such toxic effects have been reported following administration of anti-ERBB2 CAR-T cells for the treatment of metastatic malignancy, which led to CRS with subsequent respiratory distress and death due to low levels of ectopic ERBB2 in lung epithelium[ 79 ]. In order to help overcome such toxicities, a variety of strategies are being investigated. One such strategy includes the controlled removal of CAR-T cells with the use of suicide genes. There has been promise with the use of a drug inducible caspase 9 system (pro-apoptotic molecule that activates downstream pro-apoptotic caspase 3 when chemically induced) leading to apoptosis of CAR-T cells on demand[ 80 ] and with a system utilizing a truncated epidermal growth factor receptor, which allows for elimination following administration of a receptor specific antibody[ 81 ]. More recently, Amatya et al [ 82 ] developed CAR-T cells with a caspase 9 suicide gene for the treatment of multiple myeloma. Following administration of a dimerizing agent, CAR-T cells underwent apoptosis and were no longer active.

As previously mentioned, identification of a suitable TAA is imperative in the development of efficacious CAR-T cells, however highly specific TAAs are rarely identified, leading to investigation of dual- targeted CAR-T cells. Chen et al [ 83 ] developed dual-target CAR-T cells (targeting GPC3 and Asialoglycoprotein receptor 1) for the treatment of HCC. Not only did these cells demonstrate superior anticancer activity coupled with higher cytokine secretion when compared to single target CAR-T cells, but their specificity toward cellular targets may reduce the risk of on target- off tumor toxicity[ 83 ]. Recent developments have shown efficacy of a novel, split anti-GPC3 CAR-T, into two components with the use of SpyCatcher (extracellular 116 amino acid sequence linked to the intracellular domain) and SpyTag (13 amino acid peptide linked to single chain variable fragment). Such dual component delivery of CAR-T cells not only suppressed tumor growth, but displayed decreased cytokine release, representing a safer alternative when compared with conventional CAR-T cells[ 84 ]. Other perspectives include formation of a split, universal and programmable CAR system that allows for enhancement of specificity, safety and programmability of CAR delivery systems[ 85 ].

TCR engineered T cells

TCR engineered T cells are modified T cells that are able to precisely recognize tumor surface antigen peptides and MHC, rendering a response only effective when tumor cells express both antigen epitopes and MHC molecules[ 57 ]. TCR engineered T cells specific to NY-ESO-1 have demonstrated significant antitumor effects in the treatment of multiple myeloma[ 86 ] and synovial sarcomas[ 87 ]. The presence of NY-ESO-1 overexpression in HCC has made it an investigated target when developing engineered T cells in one phase II study ( NCT01967823 ), and two phase I studies ( NCT02869217 ) and ( NCT03159585 ), for which we eagerly await results. In addition, TCR engineered T cells targeting hepatitis B viral antigens in HBV related HCC have been of interest in both preclinical and clinical models[ 88 , 89 ]. Recently in November 2020, Chen et al [ 90 ] presented an abstract at the 2020 Society for Immunotherapy of Cancer, demonstrating safety and efficacy of HBV specific TCR T-cells in recurrent HBV related HCC patients post liver transplant ( NCT02719782 ).

There are currently five ongoing trials investigating TCR engineered cells targeting various TAAs in HCC (Table 2 ). All trials are investigating efficacy in advanced, unresectable HCC, with the exception of ( NCT03899415 ), which is evaluating the safety and clinical benefit of TCR engineered T cells in HBV positive HCC patients post hepatectomy or radiofrequency ablation.

Cytokine induced killer cells

Cytokine induced killer (CIK) cell therapy is a form of adaptive cell transfer that has been investigated as adjuvant therapy in patients with HCC. CIK cells are isolated from the patient’s peripheral mononuclear cells, at which point they are grown ex vivo with the addition of cytokines such as recombinant human IFN-γ, anti-CD3 monoclonal antibody, and recombinant human IL-2 prior to transfusion back into the patient; allowing for recognition and subsequent death of tumor cells[ 91 ]. In a multicenter, randomized phase III trial conducted in Korea, 230 patients were assigned to receive adjuvant CIK or no adjuvant therapy (control) following treatment with surgical resection, radiofrequency ablation or percutaneous ethanol injection ( NCT00699816 ). Median RFS was significantly prolonged in the immunotherapy group (44 mo vs 30 mo, P = 0.01), coupled with lower hazard ratios for all cause death ( P = 0.08) and cancer-related death ( P = 0.02)[ 92 ]. A 5-year follow-up study demonstrated continued efficacy of autologous CIK immunotherapy without any repeated injections ( NCT01890291 ). After an average 68.5 mo follow up, RFS was 44.8% in the immunotherapy group and 33.1% in the control group, coupled with a significantly lower risk of all-cause death (hazard ratio 0.33, 95%CI: 0.15-0.76, P = 0.006)[ 93 ]. Similar results were demonstrated in a meta-analysis and systemic review conducted by Cai et al [ 94 ] examining adjuvant CIK after invasive treatments for HCC. Pooled analysis demonstrated a significant improvement of RFS, PFS and OS in patients receiving autologous CIK immunotherapy. Although many studies have been conducted examining the safety and efficacy of CIK as an adjuvant treatment for HCC with mixed results; research is limited when examining CIK therapy as a sole treatment for unresectable HCC.

TILs

TIL therapy is an immunotherapeutic technique that involves isolation and subsequent cell culture followed by autologous administration of tumor specific T cells present in infiltrated tumors. Success of adoptive cell therapy using TIL is based on the diverse antigenic specificity displayed by TIL cells toward the tumor and the lytic capabilities possessed allowing for eradication of malignancy[ 95 ]. TILs play an essential role in cancer progression[ 96 ] and even as a predictive biomarker of response to neoadjuvant chemotherapy in a variety of malignancies[ 97 ]. After the recognition of tumor associated antigens[ 98 ], various types of TILs infiltrate to the tumor site; including NK cells, NK T cells, mucosal-associated invariant T cells, and gamma delta T cells[ 99 ]. CD4+ T helper cells on the other hand further differentiate in the periphery into a variety of subsets ( i.e. , Th1, Th2, Th9, Th17, Th22, regulatory T cells, and T follicular helper cells)[ 100 ]. CD8+ and NK cells contribute to a direct cytotoxic antitumor effect induced by a cascade of activating and inactivating receptors[ 99 ].

In a study conducted by Chew et al [ 101 ], examining immune gene expression profiles of resected tumor, HCC patient survival was positively correlated to higher expression of inflammatory immune genes. In conjunction, there was an increased presence of NK cells and T cells promoting apoptosis and reducing proliferation in the tumors of patients with longer survival, suggesting that TILs can be used as a specific immunotherapy for treatment of HCC[ 101 ]. In a hallmark randomized trial, patients who had undergone curative resection for HCC were assigned to receive adoptive immunotherapy vs no adjuvant therapy. Administration of lymphocyte infusion led to a reduced frequency of recurrence by 18%, significantly longer time to first recurrence ( P = 0.008), longer RFS ( P = 0.01) and disease- specific survival ( P = 0.04) when compared to controls[ 102 ]. A phase I trial ( NCT01462903 ) examined the use of autologous TILs in HCC patients post resection. Results demonstrated that 80% of patients remained disease free after 14-mo follow-up, while displaying a favorable side effect profile, further suggesting TIL therapy as a safe treatment method for HCC[ 103 ]. Currently an active clinical trial is investigating the safety and efficacy of autologous TILs in patients with high-risk recurrent HCC ( NCT04538313 ). Research is limited on the use of TIL immunotherapy for unresectable HCC, and we hope that further studies can be initiated using TILs alone or in combination with other therapies such as chemotherapy or ICIs.

NK cells

NK cells play an active and critical role in the innate and adaptive immune defense against viral infections and hepatocellular malignancy[ 104 ], forming as much as 50% of innate immunity cell infiltrate within the liver[ 105 ]. Several clinical studies have demonstrated the safety and efficacy of allogenic NK cell adoptive immunotherapy in the treatment of various malignancies[ 106 , 107 ] including HCC[ 108 ]. In a study conducted by Lin et al [ 108 ], patients were enrolled to receive cryoablation alone vs allogenic NK cell therapy for the treatment of unresectable HCC. Results demonstrated synergistic effects of combination therapy leading to enhanced immune function, reduction in AFP, and improved quality of life in addition to an increased median PFS (9.1 mo vs 7.6 mo, P = 0.01), higher response rate (60% vs 46.1%, P < 0.05) and DCR (85.7% vs 69.2%, P < 0.01) when compared to cryoablation alone. Similar results were demonstrated in a study conducted by Alnaggar et al [ 109 ], which investigated allogenic NK cell immunotherapy in combination with irreversible electroporation for Stage IV unresectable HCC. Efficacy of treatment was synergistic, with statistically significant lower AFP levels at 1 and 3 mo after treatment ( P < 0.01), coupled with a higher median OS (10.1 mo vs 8.9 mo, P = 0.0078) when comparing combo therapies vs electroporation alone. Currently a phase I/II study investigating allogenic NK cell therapy in patients with advanced HCC ( NCT04162158 ) is underway, as well as a phase II/III study examining the effects of autologous NK therapy when coupled with transcatheter arterial chemoembolization (TACE) for the treatment of advanced HCC ( NCT04011033 ). Combination therapy of “off the shelf” FT500 NK cells with ICIs is also being investigated in subjects with advanced solid tumors including HCC ( NCT03841110 ).

The advent of genetic modification techniques has led to the use of CAR technology to develop CAR-NK cells to improve specificity and efficacy of NK cell cytotoxicity[ 110 ]. Yu et al [ 111 ] developed a GPC3-specific NK cell for the treatment of HCC, which demonstrated in vitro cytotoxicity and cytokine production in addition to potent anti-tumor activities in HCC xenografts. Similar treatment benefits were noted with the development of c-MET specific CAR-NK cells, which demonstrated specific cytotoxicity against malignant hepatic cells in vitro [ 112 ]. While there are many ongoing clinical trials investigating CAR-NK immunotherapy for the treatment of hematological malignancies; investigation of treatment efficacy in solid tumors remains scarce.

DC-CIK cells

DC are antigen presenting cells that bridge the gap between innate and adaptive immunity, allowing for activation of naïve T cells that promote tumor-specific T cell immune response and adaptive immunity[ 113 ]. The use of in vitro generated DC combined with CIK cells has shown to be an effective and promising immunotherapy technique when used alone or in combination with other treatment options for a variety of malignancies[ 114 ]. In a study conducted by Zhou et al [ 115 ], advanced HCC patients were assigned to receive sorafenib alone vs a combination of sorafenib and DC-CIK immunotherapy. Results not only demonstrated a significant reduction in AFP levels when using combination therapy, but a significant increase in clinical benefit rate (41.9% vs 88.6%, P < 0.05) and prolonged median survival time (13.8 m vs 18.6 m, P < 0.05) while maintaining safety. Examination of combined therapy of TACE with DC-CIK therapy vs TACE alone has shown statistically prolonged OS time in HCC patients with HBV[ 116 ]. A meta-analysis of 22 studies, conducted in 2019 by Cao et al [ 117 ], has shown a prolonged survival and reduced recurrence rate of HCC when combining conventional clinical treatment and immunotherapy with DC and/or CIKs. There are currently studies recruiting participants for treatment of various solid tumors (including HCC) with DC-CIK combination immunotherapy ( NCT04214717 , NCT04476641 , NCT03190811 ).

HCC vaccines

Current advancements in medicine and immunobiology have demonstrated promising treatment strategies of cancer vaccines and oncolytic immunotherapy in patients with advanced stage cancer, leading to a variety of studies under clinical investigation[ 118 ]. Modalities include DC vaccinations, vaccines that target the antigens on tumor cells which in return activate cellular and humoral immunity causing a phagocytic activity towards the tumor cells, and oncolytic viruses that can attack and destroy tumor cells. These vaccines have both prophylactic and therapeutic aspects that can aid in the treatment of advanced cases of HCC. An up-to-date list of cancer vaccines and oncolytic virus therapies under current clinical investigation is provided (Table 3 ).

Antigen peptide vaccines

Targeting these unique antigens can contribute to a significant approach in the development of vaccines in cases of HCC. Foremost antigens include AFP, GPC3, NY-ESO-1, hTERT, and hepatocellular and melanoma antigen gene-A ( MAGE-A ) as previously mentioned[ 119 ]. GPC3 peptide, a heparan sulfate glycoprotein and member of the GPC proteoglycan group, functions through attaching to the cell membrane by a glycophosphatidylinositol anchor, further regulating several growth factors through the Wnts, hedgehog, and the BMP signaling pathways[ 120 ]. This peptide can be an ideal target for HCC vaccine development, as GPC3 is detected in the vast majority of HCC cases[ 121 ]. In a phase I trial conducted on 33 patients to ensure the safety of the GPC3-derived peptide vaccine for advanced HCC, results indicated a well-tolerated vaccine with significant immune response, and an improvement in the median OS rate, 12.2 mo (95%CI: 6.5-18.0) in patients with high GPC3-specific cytotoxic T-lymphocytes frequencies, as compared with 8.5 mo (95%CI: 3.7-13.1) in those with low GPC3-specific cytotoxic lymphocyte frequencies ( P = 0.033)[ 122 ]. However, it was not determined if these tumor-infiltrating lymphocytes detected after vaccination were GPC3 peptide-specific cytotoxic lymphocytes, prompting the initiation of a phase II trial (UMIN000005093) in patients with advanced HCC having failed sorafenib, which demonstrated induction of GPC3 peptide specific cytotoxic lymphocytes capable of infiltrating tumors[ 123 ].

DC vaccines

DCs have a potent effect on the T cell responses in HCC and other malignancies by acting as antigen presenting cells towards cytotoxic T lymphocytes[ 124 ]. Prior to administration of these vaccines to subjects, allogenic DCs are loaded with tumor antigens ex vivo , and then stimulated with cytokines such as granulocyte-macrophage colony-stimulating factor for further expansion[ 125 ]. In a recent 2016 study, DC vaccines loaded with autologous tumor cell lysate (Hepa1-6 cells) were studied using an orthotopic murine model of HCC. Treatment using this combination not only inhibited progression of murine HCC, but results were promising with a 90% survival rate compared to survival rate lower than 5% in untreated mice, suggesting alteration of the immunosuppressive tumor microenvironment as measured by lymphocyte and cytokine analysis[ 126 ]. Although DCs seem to be an attractive treatment modality, further research is required to establish better in vitro handling of DCs, better methods of cellular delivery as well as further adaptation to the in-vivo environment following cellular administration.

Oncolytic virus therapy

The use of exogenously administered viruses has paved way as a new and promising modality of targeting cancer cells and promoting neoplastic destruction following replication and subsequent lysis of tumor cells. Such actions allow for the release of antigens after lysis, which triggers antitumor activity[ 29 ]. One such virus is Pexa-Vec (pexastimogene devacirepvec, JX-594), a modified pox virus expressing granulocyte- macrophage stimulating factor that activates both innate and adaptive immune responses, remaining as the leading oncolytic virus of interest when combating HCC[ 127 , 128 ]. A randomized phase II trial conducted in patients with advanced HCC, demonstrated dose-related significant improvement in OS at high doses (14.1 mo) compared to low-dose treatment (6.7 mo), coupled with tumor regression involving one complete response[ 129 ]. Current interest has sparked trials with combination of common therapies. We eagerly await the results of Pexa-Vec with nivolumab ( NCT03071094 ), and Pexa-Vec with sorafenib (PHOCUS; NCT02562755 ) for treatment of patients with advanced HCC.

CONCLUSION

Treatment of HCC has made significant strides over the past decade since the approval of sorafenib as the first line, standard of care, molecular based treatment in 2007. More recently over the past few years four novel drugs: lenvatinib, ramucirumab, regorafenib, cabozantinib, have proven to be both safe and efficacious leading to approval for clinical use as an alternative or in addition to sorafenib. Clinical trials investigating the check point inhibitors atezolizumab, ipilimumab, nivolumab, and pembrolizumab have proven efficacy and identified new treatment modalities for HCC. As discussed in the paper adoptive immunotherapy including CAR-T cells, TCR engineered T cells, CIK cells, TIL cells, NK cells, DCs, and various vaccines have proven to be a promising therapeutic strategy for the treatment of HCC, however there are still many obstacles that need to be overcome prior to clinical application. Such challenges include identification of the ideal targeted antigen, overcoming the heterogenous and immunosuppressive environment of HCC, ensuring adequate delivery and persistence of immune cells, avoiding toxicity, and continued development of safe and cost-effective measures for cellular based treatment production and subsequent delivery to patients. The differences displayed between hepatic tumors amongst individuals across various stages of liver disease can possibly explain the difference in both clinical effects and adverse outcomes of immunotherapies studied. Therefore, we believe that the future of HCC treatment lies in the prospect of combined treatment modalities to exhibit synergistic effects, which have already entered various clinical trials as described within this paper. While most completed and ongoing studies focus on individuals with adequate underlying hepatic function (Child-Pugh Class A), it is imperative to expand studies to other patient subgroups including those with early-stage disease and those undergoing palliative treatment. We believe that continued investigation over the coming years will overcome current barriers and lead to the development of novel and multifactorial immunotherapeutic strategies allowing for great advances in the treatment of HCC.

Conflict-of-interest statement: The authors do not have any conflicts of interest relevant to this article.

Manuscript source: Invited manuscript

Peer-review started: March 12, 2021

First decision: April 6, 2021

Article in press: April 28, 2021

Specialty type: Oncology

Country/Territory of origin: United States

Peer-review report’s scientific quality classification

Grade A (Excellent): A

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

P-Reviewer: Li ZM, Pongcharoen S, Zhang L S-Editor: Gao CC L-Editor: A P-Editor: Yuan YY

1 Kim E Viatour P Hepatocellular carcinoma: old friends and new tricks Exp Mol Med 2020 52 1898 1907 33268834 10.1038/s12276-020-00527-1 PMC8080814

2 Janevska D Chaloska-Ivanova V Janevski V Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment Open Access Maced J Med Sci 2015 3 732 736 27275318 10.3889/oamjms.2015.111 PMC4877918

3 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Bray F Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 10.3322/caac.21660 33538338

4 Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 394 424 30207593 10.3322/caac.21492

5 Yang JD Altekruse SF Nguyen MH Gores GJ Roberts LR Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States Cancer 2017 123 81 89 27571320 10.1002/cncr.30246 PMC5161593

6 Yang M Parikh ND Liu H Wu E Rao H Feng B Lin A Wei L Lok AS Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States Sci Rep 2020 10 20922 33262356 10.1038/s41598-020-77515-y PMC7708980

7 Maida M Orlando E Cammà C Cabibbo G Staging systems of hepatocellular carcinoma: a review of literature World J Gastroenterol 2014 20 4141 4150 24764652 10.3748/wjg.v20.i15.4141 PMC3989950

8 Dhir M Melin AA Douaiher J Lin C Zhen WK Hussain SM Geschwind JF Doyle MB Abou-Alfa GK Are C A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma Ann Surg 2016 263 1112 1125 26813914 10.1097/SLA.0000000000001556

9 Llovet JM Zucman-Rossi J Pikarsky E Sangro B Schwartz M Sherman M Gores G Hepatocellular carcinoma Nat Rev Dis Primers 2016 2 16018 27158749 10.1038/nrdp.2016.18

10 Kinoshita A Onoda H Fushiya N Koike K Nishino H Tajiri H Staging systems for hepatocellular carcinoma: Current status and future perspectives World J Hepatol 2015 7 406 424 25848467 10.4254/wjh.v7.i3.406 PMC4381166

11 Gbolahan OB Schacht MA Beckley EW LaRoche TP O’Neil BH Pyko M Locoregional and systemic therapy for hepatocellular carcinoma J Gastrointest Oncol 2017 8 215 228 28480062 10.21037/jgo.2017.03.13 PMC5401862

12 Václav T Surgical treatment of hepatocellular carcinoma Klin Onkol 2020 33 30 33 33213163 10.14735/amko20203S30

13 Jadlowiec CC Taner T Liver transplantation: Current status and challenges World J Gastroenterol 2016 22 4438 4445 27182155 10.3748/wjg.v22.i18.4438 PMC4858627

14 Rimassa L Pressiani T Merle P Systemic Treatment Options in Hepatocellular Carcinoma Liver Cancer 2019 8 427 446 31799201 10.1159/000499765 PMC6883446

15 Sim HW Knox J Hepatocellular carcinoma in the era of immunotherapy Curr Probl Cancer 2018 42 40 48 29150141 10.1016/j.currproblcancer.2017.10.007

16 Kudo M Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma Liver Cancer 2018 7 1 19 29662829 10.1159/000487148 PMC5892376

17 Llovet JM Ricci S Mazzaferro V Hilgard P Gane E Blanc JF de Oliveira AC Santoro A Raoul JL Forner A Schwartz M Porta C Zeuzem S Bolondi L Greten TF Galle PR Seitz JF Borbath I Häussinger D Giannaris T Shan M Moscovici M Voliotis D Bruix J SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma N Engl J Med 2008 359 378 390 18650514 10.1056/NEJMoa0708857

18 Cheng AL Kang YK Chen Z Tsao CJ Qin S Kim JS Luo R Feng J Ye S Yang TS Xu J Sun Y Liang H Liu J Wang J Tak WY Pan H Burock K Zou J Voliotis D Guan Z Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 2009 10 25 34 19095497 10.1016/S1470-2045(08)70285-7

19 Alqahtani A Khan Z Alloghbi A Said Ahmed TS Ashraf M Hammouda DM Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies Medicina (Kaunas) 2019 55 10.3390/medicina55090526 PMC6780754 31450841

20 Al-Salama ZT Syed YY Scott LJ Lenvatinib: A Review in Hepatocellular Carcinoma Drugs 2019 79 665 674 30993651 10.1007/s40265-019-01116-x

21 Kudo M Finn RS Qin S Han KH Ikeda K Piscaglia F Baron A Park JW Han G Jassem J Blanc JF Vogel A Komov D Evans TRJ Lopez C Dutcus C Guo M Saito K Kraljevic S Tamai T Ren M Cheng AL Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet 2018 391 1163 1173 29433850 10.1016/S0140-6736(18)30207-1

22 Personeni N Pressiani T Rimassa L Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date J Hepatocell Carcinoma 2019 6 31 39 30775342 10.2147/JHC.S168953 PMC6362912

23 Zhu AX Park JO Ryoo BY Yen CJ Poon R Pastorelli D Blanc JF Chung HC Baron AD Pfiffer TE Okusaka T Kubackova K Trojan J Sastre J Chau I Chang SC Abada PB Yang L Schwartz JD Kudo M REACH Trial Investigators Ramucirumab vs placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Lancet Oncol 2015 16 859 870 26095784 10.1016/S1470-2045(15)00050-9

24 Zhu AX Kang YK Yen CJ Finn RS Galle PR Llovet JM Assenat E Brandi G Lim HY Pracht M Rau KM Merle P Motomura K Ohno I Daniele B Shin D Gerken G Abada P Hsu Y Kudo M REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab vs placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib J Clin Oncol 2018 36 4003

25 Cerrito L Ponziani FR Garcovich M Tortora A Annicchiarico BE Pompili M Siciliano M Gasbarrini A Regorafenib: a promising treatment for hepatocellular carcinoma Expert Opin Pharmacother 2018 19 1941 1948 30345837 10.1080/14656566.2018.1534956

26 Bruix J Qin S Merle P Granito A Huang YH Bodoky G Pracht M Yokosuka O Rosmorduc O Breder V Gerolami R Masi G Ross PJ Song T Bronowicki JP Ollivier-Hourmand I Kudo M Cheng AL Llovet JM Finn RS LeBerre MA Baumhauer A Meinhardt G Han G RESORCE Investigators Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2017 389 56 66 27932229 10.1016/S0140-6736(16)32453-9

27 Abou-Alfa GK Meyer T Cheng AL El-Khoueiry AB Rimassa L Ryoo BY Cicin I Merle P Chen Y Park JW Blanc JF Bolondi L Klümpen HJ Chan SL Zagonel V Pressiani T Ryu MH Venook AP Hessel C Borgman-Hagey AE Schwab G Kelley RK Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma N Engl J Med 2018 379 54 63 29972759 10.1056/NEJMoa1717002 PMC7523244

28 Hargadon KM Johnson CE Williams CJ Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors Int Immunopharmacol 2018 62 29 39 29990692 10.1016/j.intimp.2018.06.001

29 Nakano S Eso Y Okada H Takai A Takahashi K Seno H Recent Advances in Immunotherapy for Hepatocellular Carcinoma Cancers (Basel) 2020 12 10.3390/cancers12040775 PMC7226090 32218257

30 Gao Q Wang XY Qiu SJ Yamato I Sho M Nakajima Y Zhou J Li BZ Shi YH Xiao YS Xu Y Fan J Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 2009 15 971 979 19188168 10.1158/1078-0432.CCR-08-1608

31 Fritz JM Lenardo MJ Development of immune checkpoint therapy for cancer J Exp Med 2019 216 1244 1254 31068379 10.1084/jem.20182395 PMC6547853

32 Lee MS Ryoo BY Hsu CH Numata K Stein S Verret W Hack SP Spahn J Liu B Abdullah H Wang Y He AR Lee KH GO30140 investigators Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study Lancet Oncol 2020 21 808 820 32502443 10.1016/S1470-2045(20)30156-X

33 Finn RS Qin S Ikeda M Galle PR Ducreux M Kim TY Kudo M Breder V Merle P Kaseb AO Li D Verret W Xu DZ Hernandez S Liu J Huang C Mulla S Wang Y Lim HY Zhu AX Cheng AL IMbrave150 Investigators Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma N Engl J Med 2020 382 1894 1905 32402160 10.1056/NEJMoa1915745

34 Hack SP Spahn J Chen M Cheng AL Kaseb A Kudo M Lee HC Yopp A Chow P Qin S IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation Future Oncol 2020 16 975 989 32352320 10.2217/fon-2020-0162

35 Yau T Kang YK Kim TY El-Khoueiry AB Santoro A Sangro B Melero I Kudo M Hou MM Matilla A Tovoli F Knox JJ Ruth He A El-Rayes BF Acosta-Rivera M Lim HY Neely J Shen Y Wisniewski T Anderson J Hsu C Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial JAMA Oncol 2020 10.1001/jamaoncol.2020.4564 PMC7530824 33001135

36 El-Khoueiry AB Sangro B Yau T Crocenzi TS Kudo M Hsu C Kim TY Choo SP Trojan J Welling TH Rd Meyer T Kang YK Yeo W Chopra A Anderson J Dela Cruz C Lang L Neely J Tang H Dastani HB Melero I Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 2017 389 2492 2502 28434648 10.1016/S0140-6736(17)31046-2 PMC7539326

37 Yau T Park J Finn R Cheng AL Mathurin P Edeline J Kudo M Han KH Harding J Merle P CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Ann Oncol 2019 30 v874 v875

38 Kwok G Yau TC Chiu JW Tse E Kwong YL Pembrolizumab (Keytruda) Hum Vaccin Immunother 2016 12 2777 2789 27398650 10.1080/21645515.2016.1199310 PMC5137544

39 Zhu AX Finn RS Edeline J Cattan S Ogasawara S Palmer D Verslype C Zagonel V Fartoux L Vogel A Sarker D Verset G Chan SL Knox J Daniele B Webber AL Ebbinghaus SW Ma J Siegel AB Cheng AL Kudo M KEYNOTE-224 investigators Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Lancet Oncol 2018 19 940 952 29875066 10.1016/S1470-2045(18)30351-6

40 Finn RS Ryoo BY Merle P Kudo M Bouattour M Lim HY Breder V Edeline J Chao Y Ogasawara S Yau T Garrido M Chan SL Knox J Daniele B Ebbinghaus SW Chen E Siegel AB Zhu AX Cheng AL KEYNOTE-240 investigators Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial J Clin Oncol 2020 38 193 202 31790344 10.1200/JCO.19.01307

41 Özdemir F Baskiran A The Importance of AFP in Liver Transplantation for HCC J Gastrointest Cancer 2020 51 1127 1132 32845425 10.1007/s12029-020-00486-w

42 Mizejewski GJ Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states Obstet Gynecol Surv 2003 58 804 826 14668662 10.1097/01.OGX.0000099770.97668.18

43 Zhu W Peng Y Wang L Hong Y Jiang X Li Q Liu H Huang L Wu J Celis E Merchen T Kruse E He Y Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy Hepatology 2018 68 574 589 29443377 10.1002/hep.29844 PMC7368991

44 Liu H Xu Y Xiang J Long L Green S Yang Z Zimdahl B Lu J Cheng N Horan LH Liu B Yan S Wang P Diaz J Jin L Nakano Y Morales JF Zhang P Liu LX Staley BK Priceman SJ Brown CE Forman SJ Chan VW Liu C Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer Clin Cancer Res 2017 23 478 488 27535982 10.1158/1078-0432.CCR-16-1203

45 Montalbano M Georgiadis J Masterson AL McGuire JT Prajapati J Shirafkan A Rastellini C Cicalese L Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review) Oncol Rep 2017 37 1291 1300 28098909 10.3892/or.2017.5387

46 Kaseb AO Hassan M Lacin S Abdel-Wahab R Amin HM Shalaby A Wolff RA Yao J Rashid A Vennapusa B Feng J Ohtomo T Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma Oncotarget 2016 7 69916 69926 27655712 10.18632/oncotarget.12066 PMC5342524

47 Zhou F Shang W Yu X Tian J Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment Med Res Rev 2018 38 741 767 28621802 10.1002/med.21455

48 Jiang Z Jiang X Chen S Lai Y Wei X Li B Lin S Wang S Wu Q Liang Q Liu Q Peng M Yu F Weng J Du X Pei D Liu P Yao Y Xue P Li P Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma Front Immunol 2016 7 690 28123387 10.3389/fimmu.2016.00690 PMC5225101

49 Li R Gong J Xiao C Zhu S Hu Z Liang J Li X Yan X Zhang X Li D Liu W Chong Y Jie Y A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma Genomics 2020 112 5101 5114 32941982 10.1016/j.ygeno.2020.09.026

50 Gordeeva O Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy Semin Cancer Biol 2018 53 75 89 30171980 10.1016/j.semcancer.2018.08.006

51 Thomas R Al-Khadairi G Roelands J Hendrickx W Dermime S Bedognetti D Decock J NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives Front Immunol 2018 9 947 29770138 10.3389/fimmu.2018.00947 PMC5941317

52 Bohne F Chmielewski M Ebert G Wiegmann K Kürschner T Schulze A Urban S Krönke M Abken H Protzer U T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes Gastroenterology 2008 134 239 247 18166356 10.1053/j.gastro.2007.11.002

53 Kruse RL Shum T Tashiro H Barzi M Yi Z Whitten-Bauer C Legras X Bissig-Choisat B Garaigorta U Gottschalk S Bissig KD HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice Cytotherapy 2018 20 697 705 29631939 10.1016/j.jcyt.2018.02.002 PMC6038120

54 Krause J von Felden J Casar C Fründt TW Galaski J Schmidt C Jung C Ittrich H Weidemann SA Krech T Heumann A Li J Fischer L Sauter G Lohse AW Wege H Schulze K Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype BMC Cancer 2020 20 1130 33225916 10.1186/s12885-020-07580-z PMC7682021

55 Ma Y Wang Z Gong R Li L Wu H Jin H Specific cytotoxicity of MUC1 chimeric antigen receptor-engineered Jurkat T cells against hepatocellular carcinoma Acad J Second Mil Med Univ 2014 5 1177 1182

56 Mizukoshi E Nakamoto Y Marukawa Y Arai K Yamashita T Tsuji H Kuzushima K Takiguchi M Kaneko S Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma Hepatology 2006 43 1284 1294 16729333 10.1002/hep.21203

57 Mizukoshi E Kaneko S Immune cell therapy for hepatocellular carcinoma J Hematol Oncol 2019 12 52 31142330 10.1186/s13045-019-0742-5 PMC6542133

58 Benmebarek MR Karches CH Cadilha BL Lesch S Endres S Kobold S Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells Int J Mol Sci 2019 20 10.3390/ijms20061283 PMC6470706 30875739

59 Chen Y E CY Gong ZW Liu S Wang ZX Yang YS Zhang XW Chimeric antigen receptor-engineered T-cell therapy for liver cancer Hepatobiliary Pancreat Dis Int 2018 17 301 309 29861325 10.1016/j.hbpd.2018.05.005

60 Ping Y Liu C Zhang Y T-cell receptor-engineered T cells for cancer treatment: current status and future directions Protein Cell 2018 9 254 266 28108950 10.1007/s13238-016-0367-1 PMC5829268

61 Rochigneux P Chanez B De Rauglaudre B Mitry E Chabannon C Gilabert M Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials Cancers (Basel) 2021 13 10.3390/cancers13020271 PMC7828372 33450845

62 Kershaw MH Westwood JA Darcy PK Gene-engineered T cells for cancer therapy Nat Rev Cancer 2013 13 525 541 23880905 10.1038/nrc3565

63 Shi D Shi Y Kaseb AO Qi X Zhang Y Chi J Lu Q Gao H Jiang H Wang H Yuan D Ma H Li Z Zhai B Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials Clin Cancer Res 2020 26 3979 3989 32371538 10.1158/1078-0432.CCR-19-3259

64 Dai H Tong C Shi D Chen M Guo Y Chen D Han X Wang H Wang Y Shen P Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial Oncoimmunology 2020 9 1846926 33312759 10.1080/2162402X.2020.1846926 PMC7714531

65 Caruana I Savoldo B Hoyos V Weber G Liu H Kim ES Ittmann MM Marchetti D Dotti G Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes Nat Med 2015 21 524 529 25849134 10.1038/nm.3833 PMC4425589

66 Mardomi A Abediankenari S Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors? Cancer Microenviron 2018 11 93 96 29589335 10.1007/s12307-018-0208-2 PMC6008262

67 Katz SC Burga RA McCormack E Wang LJ Mooring W Point GR Khare PD Thorn M Ma Q Stainken BF Assanah EO Davies R Espat NJ Junghans RP Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases Clin Cancer Res 2015 21 3149 3159 25850950 10.1158/1078-0432.CCR-14-1421 PMC4506253

68 Riley RS June CH Langer R Mitchell MJ Delivery technologies for cancer immunotherapy Nat Rev Drug Discov 2019 18 175 196 30622344 10.1038/s41573-018-0006-z PMC6410566

69 Ma W Zhu D Li J Chen X Xie W Jiang X Wu L Wang G Xiao Y Liu Z Wang F Li A Shao D Dong W Liu W Yuan Y Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment Theranostics 2020 10 1281 1295 31938065 10.7150/thno.40291 PMC6956810

70 Franchina DG Dostert C Brenner D Reactive Oxygen Species: Involvement in T Cell Signaling and Metabolism Trends Immunol 2018 39 489 502 29452982 10.1016/j.it.2018.01.005

71 Dal Bo M De Mattia E Baboci L Mezzalira S Cecchin E Assaraf YG Toffoli G New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma Drug Resist Updat 2020 51 100702 32371296 10.1016/j.drup.2020.100702

72 Ligtenberg MA Mougiakakos D Mukhopadhyay M Witt K Lladser A Chmielewski M Riet T Abken H Kiessling R Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity J Immunol 2016 196 759 766 26673145 10.4049/jimmunol.1401710 PMC4705591

73 Wu AA Drake V Huang HS Chiu S Zheng L Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells Oncoimmunology 2015 4 e1016700 26140242 10.1080/2162402X.2015.1016700 PMC4485788

74 Gargett T Yu W Dotti G Yvon ES Christo SN Hayball JD Lewis ID Brenner MK Brown MP GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade Mol Ther 2016 24 1135 1149 27019998 10.1038/mt.2016.63 PMC4923328

75 Rupp LJ Schumann K Roybal KT Gate RE Ye CJ Lim WA Marson A CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells Sci Rep 2017 7 737 28389661 10.1038/s41598-017-00462-8 PMC5428439

76 Shimabukuro-Vornhagen A Gödel P Subklewe M Stemmler HJ Schlößer HA Schlaak M Kochanek M Böll B von Bergwelt-Baildon MS Cytokine release syndrome J Immunother Cancer 2018 6 56 29907163 10.1186/s40425-018-0343-9 PMC6003181

77 Yáñez L Sánchez-Escamilla M Perales MA CAR T Cell Toxicity: Current Management and Future Directions Hemasphere 2019 3 e186 31723825 10.1097/HS9.0000000000000186 PMC6746032

78 Gust J Taraseviciute A Turtle CJ Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies CNS Drugs 2018 32 1091 1101 30387077 10.1007/s40263-018-0582-9 PMC7295115

79 Morgan RA Yang JC Kitano M Dudley ME Laurencot CM Rosenberg SA Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 2010 18 843 851 20179677 10.1038/mt.2010.24 PMC2862534

80 Gargett T Brown MP The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells Front Pharmacol 2014 5 235 25389405 10.3389/fphar.2014.00235 PMC4211380

81 Paszkiewicz PJ Fräßle SP Srivastava S Sommermeyer D Hudecek M Drexler I Sadelain M Liu L Jensen MC Riddell SR Busch DH Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia J Clin Invest 2016 126 4262 4272 27760047 10.1172/JCI84813 PMC5096899

82 Amatya C Pegues MA Lam N Vanasse D Geldres C Choi S Hewitt SM Feldman SA Kochenderfer JN Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7 Mol Ther 2021 29 702 717 33129371 10.1016/j.ymthe.2020.10.008 PMC7854354

83 Chen C Li K Jiang H Song F Gao H Pan X Shi B Bi Y Wang H Li Z Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma Cancer Immunol Immunother 2017 66 475 489 28035433 10.1007/s00262-016-1949-8 PMC11028818

84 Liu X Wen J Yi H Hou X Yin Y Ye G Wu X Jiang X Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release Ther Adv Med Oncol 2020 12 1758835920910347 32215059 10.1177/1758835920910347 PMC7065297

85 Cho JH Collins JJ Wong WW Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses Cell 2018 173 1426 1438.e11 29706540 10.1016/j.cell.2018.03.038 PMC5984158

86 Rapoport AP Stadtmauer EA Binder-Scholl GK Goloubeva O Vogl DT Lacey SF Badros AZ Garfall A Weiss B Finklestein J Kulikovskaya I Sinha SK Kronsberg S Gupta M Bond S Melchiori L Brewer JE Bennett AD Gerry AB Pumphrey NJ Williams D Tayton-Martin HK Ribeiro L Holdich T Yanovich S Hardy N Yared J Kerr N Philip S Westphal S Siegel DL Levine BL Jakobsen BK Kalos M June CH NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Nat Med 2015 21 914 921 26193344 10.1038/nm.3910 PMC4529359

87 D’Angelo SP Melchiori L Merchant MS Bernstein D Glod J Kaplan R Grupp S Tap WD Chagin K Binder GK Basu S Lowther DE Wang R Bath N Tipping A Betts G Ramachandran I Navenot JM Zhang H Wells DK Van Winkle E Kari G Trivedi T Holdich T Pandite L Amado R Mackall CL Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma Cancer Discov 2018 8 944 957 29891538 10.1158/2159-8290.CD-17-1417 PMC8092079

88 Gehring AJ Xue SA Ho ZZ Teoh D Ruedl C Chia A Koh S Lim SG Maini MK Stauss H Bertoletti A Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines J Hepatol 2011 55 103 110 21145860 10.1016/j.jhep.2010.10.025

89 Tan AT Yang N Lee Krishnamoorthy T Oei V Chua A Zhao X Tan HS Chia A Le Bert N Low D Tan HK Kumar R Irani FG Ho ZZ Zhang Q Guccione E Wai LE Koh S Hwang W Chow WC Bertoletti A Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy Gastroenterology 2019 156 1862 1876.e9 30711630 10.1053/j.gastro.2019.01.251

90 Chen W Cheng J Zheng X Yang F Fam R Koh S Wai L-E Wang T Bertoletti A Zhang Q 273 Phase i study of LioCyx-M, autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, in recurrent HBV-related hepatocellular carcinoma (HCC) post-liver transplantation J Immunother Cancer 2020 8 A167 A167

91 Zhang R Zhang Z Liu Z Wei D Wu X Bian H Chen Z Adoptive cell transfer therapy for hepatocellular carcinoma Front Med 2019 13 3 11 30659408 10.1007/s11684-019-0684-x

92 Lee JH Lee JH Lim YS Yeon JE Song TJ Yu SJ Gwak GY Kim KM Kim YJ Lee JW Yoon JH Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma Gastroenterology 2015 148 1383 91.e6 25747273 10.1053/j.gastro.2015.02.055

93 Lee JH Lee JH Lim YS Yeon JE Song TJ Yu SJ Gwak GY Kim KM Kim YJ Lee JW Yoon JH Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up Cancer Immunol Immunother 2019 68 23 32 30232520 10.1007/s00262-018-2247-4 PMC6326973

94 Cai XR Li X Lin JX Wang TT Dong M Chen ZH Jia CC Hong YF Lin Q Wu XY Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review Oncotarget 2017 8 31318 31328 28412743 10.18632/oncotarget.15454 PMC5458210

95 Forget MA Tavera RJ Haymaker C Ramachandran R Malu S Zhang M Wardell S Fulbright OJ Toth CL Gonzalez AM Thorsen ST Flores E Wahl A Peng W Amaria RN Hwu P Bernatchez C A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes Front Immunol 2017 8 908 28824634 10.3389/fimmu.2017.00908 PMC5539190

96 Gomez Perdiguero E Geissmann F Cancer immunology. Identifying the infiltrators Science 2014 344 801 802 24855239 10.1126/science.1255117

97 Zeng DQ Yu YF Ou QY Li XY Zhong RZ Xie CM Hu QG Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer Oncotarget 2016 7 13765 13781 26871598 10.18632/oncotarget.7282 PMC4924677

98 Kumar S Skeen MJ Adiri Y Yoon H Vezys VD Lukacher AE Evavold BD Ziegler HK Boss JM A cytokine promoter/yellow fluorescent protein reporter transgene serves as an early activation marker of lymphocyte subsets Cell Immunol 2005 237 131 140 16405934 10.1016/j.cellimm.2005.11.003

99 Piñeiro Fernández J Luddy KA Harmon C O’Farrelly C Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function Int J Mol Sci 2019 20 10.3390/ijms20174131 PMC6747260 31450598

100 Golubovskaya V Wu L Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy Cancers (Basel) 2016 8 10.3390/cancers8030036 PMC4810120 26999211

101 Chew V Tow C Teo M Wong HL Chan J Gehring A Loh M Bolze A Quek R Lee VK Lee KH Abastado JP Toh HC Nardin A Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients J Hepatol 2010 52 370 379 19720422 10.1016/j.jhep.2009.07.013

102 Takayama T Sekine T Makuuchi M Yamasaki S Kosuge T Yamamoto J Shimada K Sakamoto M Hirohashi S Ohashi Y Kakizoe T Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial Lancet 2000 356 802 807 11022927 10.1016/S0140-6736(00)02654-4

103 Jiang SS Tang Y Zhang YJ Weng DS Zhou ZG Pan K Pan QZ Wang QJ Liu Q He J Zhao JJ Li J Chen MS Chang AE Li Q Xia JC A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma Oncotarget 2015 6 41339 41349 26515587 10.18632/oncotarget.5463 PMC4747409

104 Liu P Chen L Zhang H Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy J Immunol Res 2018 2018 1206737 30255103 10.1155/2018/1206737 PMC6142725

105 Gao B Jeong WI Tian Z Liver: An organ with predominant innate immunity Hepatology 2008 47 729 736 18167066 10.1002/hep.22034

106 Lin M Alnaggar M Liang S Wang X Liang Y Zhang M Chen J Niu L Xu K An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer Oncotarget 2017 8 101795 101807 29254205 10.18632/oncotarget.21974 PMC5731915

107 Lin M Liang SZ Wang XH Liang YQ Zhang MJ Niu LZ Chen JB Li HB Xu KC Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer Immunol Res 2017 65 880 887 28508945 10.1007/s12026-017-8927-x

108 Lin M Liang S Wang X Liang Y Zhang M Chen J Niu L Xu K Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer Oncotarget 2017 8 81967 81977 29137237 10.18632/oncotarget.17804 PMC5669863

109 Alnaggar M Lin M Mesmar A Liang S Qaid A Xu K Chen J Niu L Yin Z Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome Cell Physiol Biochem 2018 48 1882 1893 30092590 10.1159/000492509

110 Nowakowska P Romanski A Miller N Odendahl M Bonig H Zhang C Seifried E Wels WS Tonn T Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies Cancer Immunol Immunother 2018 67 25 38 28879551 10.1007/s00262-017-2055-2 PMC11028154

111 Yu M Luo H Fan M Wu X Shi B Di S Liu Y Pan Z Jiang H Li Z Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma Mol Ther 2018 26 366 378 29339014 10.1016/j.ymthe.2017.12.012 PMC5835122

112 Liu B Liu ZZ Zhou ML Lin JW Chen XM Li Z Gao WB Yu ZD Liu T Development of cMETspecific chimeric antigen receptorengineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells Mol Med Rep 2019 20 2823 2831 31524233 10.3892/mmr.2019.10529 PMC6691195

113 Gardner A de Mingo Pulido Á Ruffell B Dendritic Cells and Their Role in Immunotherapy Front Immunol 2020 11 924 32508825 10.3389/fimmu.2020.00924 PMC7253577

114 Wang S Wang X Zhou X Lyerly HK Morse MA Ren J DC-CIK as a widely applicable cancer immunotherapy Expert Opin Biol Ther 2020 20 601 607 32033522 10.1080/14712598.2020.1728250

115 Zhou Z Qin H Weng L Ni Y Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma J BUON 2019 24 615 621 31128014

116 Zhang J Li H Gao D Zhang B Zheng M Lun M Wei M Duan R Guo M Hua J Liu Q Bai J Liu H Zheng J Yao H A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE Cancer Biol Ther 2018 19 475 483 29400599 10.1080/15384047.2018.1433501 PMC5927715

117 Cao J Kong FH Liu X Wang XB Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis World J Gastroenterol 2019 25 3649 3663 31367163 10.3748/wjg.v25.i27.3649 PMC6658393

118 Guo ZS Lu B Guo Z Giehl E Feist M Dai E Liu W Storkus WJ He Y Liu Z Bartlett DL Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics J Immunother Cancer 2019 7 6 30626434 10.1186/s40425-018-0495-7 PMC6325819

119 Park R Eshrat F Al-Jumayli M Saeed A Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma Vaccines (Basel) 2020 8 10.3390/vaccines8030447 PMC7563532 32784389

120 Filmus J Capurro M Rast J Glypicans Genome Biol 2008 9 224 18505598 10.1186/gb-2008-9-5-224 PMC2441458

121 Nobuoka D Yoshikawa T Sawada Y Fujiwara T Nakatsura T Peptide vaccines for hepatocellular carcinoma Hum Vaccin Immunother 2013 9 210 212 23442593 10.4161/hv.22473 PMC3667940

122 Sawada Y Yoshikawa T Nobuoka D Shirakawa H Kuronuma T Motomura Y Mizuno S Ishii H Nakachi K Konishi M Nakagohri T Takahashi S Gotohda N Takayama T Yamao K Uesaka K Furuse J Kinoshita T Nakatsura T Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival Clin Cancer Res 2012 18 3686 3696 22577059 10.1158/1078-0432.CCR-11-3044

123 Shimizu Y Suzuki T Yoshikawa T Tsuchiya N Sawada Y Endo I Nakatsura T Cancer immunotherapy-targeted glypican-3 or neoantigens Cancer Sci 2018 109 531 541 29285841 10.1111/cas.13485 PMC5834776

124 Fan J Han J Li J Gu A Yin D Song F Wang L Yi Y The expression and function of immunoglobulin-like transcript 4 in dendritic cells from patients with hepatocellular carcinoma Hum Immunol 2020 81 714 725 33228921 10.1016/j.humimm.2020.10.003

125 Gu YZ Zhao X Song XR Ex vivo pulsed dendritic cell vaccination against cancer Acta Pharmacol Sin 2020 41 959 969 32366940 10.1038/s41401-020-0415-5 PMC7470877

126 Wang Q Luan W Warren L Kadri H Kim KW Goz V Blank S Isabel Fiel M Hiotis SP Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma Ann Surg Oncol 2016 23 574 582 26786094 10.1245/s10434-015-5035-9

127 Kim JH Oh JY Park BH Lee DE Kim JS Park HE Roh MS Je JE Yoon JH Thorne SH Kirn D Hwang TH Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF Mol Ther 2006 14 361 370 16905462 10.1016/j.ymthe.2006.05.008

128 Parato KA Breitbach CJ Le Boeuf F Wang J Storbeck C Ilkow C Diallo JS Falls T Burns J Garcia V Kanji F Evgin L Hu K Paradis F Knowles S Hwang TH Vanderhyden BC Auer R Kirn DH Bell JC The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers Mol Ther 2012 20 749 758 22186794 10.1038/mt.2011.276 PMC3321594

129 Heo J Reid T Ruo L Breitbach CJ Rose S Bloomston M Cho M Lim HY Chung HC Kim CW Burke J Lencioni R Hickman T Moon A Lee YS Kim MK Daneshmand M Dubois K Longpre L Ngo M Rooney C Bell JC Rhee BG Patt R Hwang TH Kirn DH Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med 2013 19 329 336 23396206 10.1038/nm.3089 PMC4268543